I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Idiopathic dilated cardiomyopathy (IDC) remains the third most common cause of heart failure behind coronary artery disease and hypertension. The incidence of IDC is 5.5 cases per 100,000 per year, and the prevalence is 36 cases per 100,000 people, which greatly increases medical and social burdens.\[[@ref1][@ref2]\] The annual mortality rate ranges from 10% to 13% after the diagnosis of IDC is established.\[[@ref3]\] Despite remarkable progress in pharmacological therapies, particularly the use of beta-blockers and angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), and device implantation, considerable morbidity and mortality of IDC patients remain a challenge for physicians. An effective risk stratification technique might improve the management of IDC patients. Currently, numerous clinical covariates have been well-documented to predict the prognosis of dilated cardiomyopathy (DCM) patients. These include advanced age, protodiastolic gallop, ventricular arrhythmia, and more commonly used parameters such as left ventricular ejection fraction (LVEF), QRS duration, and New York Heart Association (NYHA) functional class.\[[@ref4][@ref5][@ref6]\] Several factors are widely used in routine practice. For example, LVEF is the key determinant of device implantation to primarily prevent sudden cardiac death (SCD) according to the latest guidelines.\[[@ref7]\] However, large risk stratification challenges remain due to insufficient sensitivity and specificity of these known predictors.

Attention has recently focused on QRS-T angles, which address the deviations between ventricular depolarization and repolarization.\[[@ref8]\] The spatial QRS-T angle shows its predictive value in the general population and certain clinical patients, but research and utility are limited because of the inconvenience of its acquisition from the standard 12-lead electrocardiogram (ECG). Instead, the frontal QRS-T angle is easy to obtain by visually reviewing the ECG report. The significance of the frontal QRS-T angle has rarely been studied in DCM patients, except in one study of nonischemic DCM (NIDCM) with a relatively mixed population and a majority of white and black patients.\[[@ref9]\] The NIDCM population is a relatively mixed population because the etiology of DCM in this population is varied, including primary valvular diseases and myocarditis, which compromise the detection power of the frontal QRS-T angle in a more specific IDC population. Therefore, we conducted a prospective study to investigate the long-term predictive information from frontal QRS-T angles in Chinese patients with homogenous IDC.

M[ETHODS]{.smallcaps} {#sec1-2}
=====================

Patients {#sec2-1}
--------

The study enrolled 509 consecutive patients with IDC admitted to a tertiary hospital (Affiliated Drum Tower Hospital, Nanjing University School of Medicine) between February 2008 and December 2013. All demographic information and clinical history were obtained by thorough communication. All patients underwent careful physical examination, 12-lead ECG, chest radiography, and echocardiography, on which the diagnosis of DCM was based. The diagnosis of IDC was largely made according to the definition of the World Health Organization/International Society and Federation of Cardiology Task Force\[[@ref10]\] and was restricted to patients with LVEF \<45%. Because ventricular pacing can change the morphology and polarity of QRS and T waves and, thus, affect the frontal QRS-T angle, we excluded patients with a permanent pacemaker, including cardiac resynchronization therapy. All patients had a minimum duration of 6 months since symptom onset. At the day of discharge, a 12-lead ECG examination was reperformed on each patient to evaluate the frontal QRS-T angle change after optimized therapy. The Local Ethics Committee approved this study, and informed consistent was obtained from all patients. The study was conducted according to the principles of the *Declaration of Helsinki*.

Electrocardiogram, 24-h electrocardiogram, and echocardiography {#sec2-2}
---------------------------------------------------------------

A 12-lead ECG was recorded for all patients at admission, discharge, and rehospitalization using the ECG-1350p machine (Nihon Kohden Corp., Tokyo, Japan). The ECG recorded at admission was used to estimate the frontal QRS-T angles for prognostic analysis. A paper speed of 25 mm/s and a voltage of 1 mV/10 mm were applied. The PR interval, QRS duration, and QT interval were measured as previously described.\[[@ref11]\] QT intervals corrected for heart rates were generated using the Bazett\'s formula. The presence or absence of left bundle branch block (LBBB) and right bundle branch block was determined by two experienced cardiologists. Electrocardiographic reports of the P-wave axis, QRS axis, and T-wave axis were manually checked, and the frontal QRS-T angle was calculated as the absolute value of the difference between QRS and T wave axes.

Twenty-four hour ECG recordings were performed in 313 patients. During the examination, daily-intensity activities were encouraged. Nonsustained ventricular tachycardia (NSVT) was defined as more than three consecutive beats of ventricular prematurely. The number of NSVT in 24 h was calculated, as well as that of premature ventricular complexes (PVC).

Echocardiography was performed in all patients with the iE33 xMATRIX echo system (Philips, Eindhoven, the Netherlands) and was reviewed by experienced operators who were blind to the ECG results and clinical status of patients. Standard apical four- and two-chamber and long axis views were used. Baseline left ventricular end-diastolic diameter (LVEDd), left ventricular end-systolic diameter, left atrial diameter, interventricular septum thickness, left ventricular posterior wall thickness, LVEF, and pulmonary arterial pressure were calculated according to the American Society of Echocardiography.\[[@ref12]\]

Follow-up and endpoints {#sec2-3}
-----------------------

Follow-up was conducted every 6 months through telephone interviews and medical records. The primary endpoint was all-cause death. Two additional secondary endpoints were also defined as follows: (1) cardiac death, including sudden death and death from worsening heart failure and (2) rehospitalization due to decompensated heart failure. An investigator (Jian-Zhou Chen) who was blind to the ECG results and clinical status performed the clinical outcome data collection.

Statistical analysis {#sec2-4}
--------------------

Baseline characteristics stratified by the dichotomous presence or absence of a frontal QRS-T angle \>90° were available for all patients. The cutoff of 90° was applied in our study based on results of numerous published studies.\[[@ref9][@ref13][@ref14]\] Categorical data were expressed as number (percentage) whereas continuous data were presented as the mean ± standard deviation (SD) or median (interquartile range, IQR) where appropriate. Categorical variables were compared by Chi-square test, and continuous variables were compared by unpaired Student\'s *t*-test or the Mann-Whitney *U* test. Survival analyses were performed for all three endpoints. Survival curves were estimated by the Kaplan-Meier method and compared with the log-rank test. The associations between baseline covariates and each endpoint were first tested by a univariate Cox proportional hazards model, and variables with *P* \< 0.05 were entered into the multivariable model to identify independent predictors for each endpoint. The results for both univariate and multivariable analyses were reported as hazard ratios (*HR*s) and 95% confidence intervals (*CI*s). Changes in frontal QRS-T angles from admission to discharge were assessed by Wilcoxon match-pairs analysis. The correlation between frontal QRS-T angle and well-established risk factors (LVEF, brain natriuretic peptide \[BNP\], and NYHA functional class) were analyzed by Spearman correlation test. All analyses were conducted using the statistical software SPSS version 17.0 (Chicago, IL, USA). A two-tailed *P* \< 0.05 was considered statistically significant.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

A total of 532 consecutive patients met the inclusion criteria. Twenty-three patients (4.3%) were lost to follow-up; therefore, complete follow-up was obtained in 509 (95.7%) patients. The mean age was 63 ± 16 years, LVEF was 33 ± 8%, and NYHA functional class ≥III was 71% \[[Table 1](#T1){ref-type="table"}\]. The mean QRS-T angle was 107 ± 54°. One hundred ninety-three (37.9%) patients had a QRS-T angle ≤90°, and 316 patients (62.1%) had a QRS-T angle \>90°. Compared to patients with QRS-T angles ≤90°, patients with wide angles were more likely to have diabetes, more severe symptomatic heart failure (HF) evidenced by a higher NYHA functional class rating, longer symptom duration, a lower LVEF, a higher LVEDd and a higher BNP level, coupled with higher rates of loop diuretic and aldosterone antagonist treatments. Consistently, a lower beta-blocker treatment rate was observed in patients with wide QRS-T angles. In addition, patients with QRS-T angles \>90° had a longer PR interval, QRS duration, and QT interval and higher T-wave axis and leftward QRS axis. A higher percentage of LBBB and higher numbers of PVC and NSVT were also observed.

###### 

Baseline characteristics stratified by QRS-T angle

  Items                              All patients (*n* = 509)   QRS-T angle ≤90° (*n* = 193)   QRS-T angle \>90° (*n* = 316)   Statistical value   *P*
  ---------------------------------- -------------------------- ------------------------------ ------------------------------- ------------------- ---------
  Age (years)                        63 ± 16                    63 ± 18                        64 ± 15                         −0.207\*            0.836
  Male                               338 (66)                   133 (69)                       205 (65)                        0.876^†^            0.349
  Current smoker                     147 (29)                   52 (27)                        95 (30)                         0.568^†^            0.467
  Diabetes mellitus                  116 (23)                   32 (17)                        84 (27)                         6.812^†^            0.009
  Hypertension                       195 (38)                   77 (40)                        118 (37)                        0.331^†^            0.565
  Atrial fibrillation                150 (29)                   60 (31)                        90 (28)                         0.392^†^            0.531
  Duration of CHF \>1 (years)        277 (54)                   88 (46)                        189 (60)                        9.760^†^            0.002
  Clinical variables                                                                                                                               
   NYHA class ≥III                   360 (71)                   117 (61)                       243 (77)                        15.333^†^           \<0.001
   Beta-blockers                     369 (72)                   152 (79)                       217 (69)                        6.112^†^            0.013
   ACEI/ARB                          427 (84)                   173 (90)                       254 (80)                        7.598^†^            0.006
   Loop diuretics                    434 (85)                   151 (78)                       283 (90)                        12.218^†^           \<0.001
   Spironolactone                    370 (73)                   125 (65)                       245 (78)                        9.835^†^            0.002
   Digoxin                           226 (44)                   87 (45)                        139 (44)                        0.058^†^            0.810
   Aspirin                           186 (37)                   70 (36)                        116 (37)                        0.010^†^            0.920
   Warfarin                          47 (9)                     25 (13)                        22 (7)                          5.132^†^            0.023
   Amiodarone                        26 (5)                     12 (6)                         14 (4)                          0.790^†^            0.374
   Systolic blood pressure (mmHg)    125 ± 20                   127 ± 18                       125 ± 21                        0.983\*             0.326
   Diastolic blood pressure (mmHg)   78 ± 13                    79 ± 13                        78 ± 13                         0.796\*             0.426
   Heart rate (beats/min)            77 ± 22                    76 ± 21                        77 ± 23                         −0.510\*            0.610
   ICD                               56 (11)                    14 (7)                         42 (13)                         4.460^†^            0.035
  ECG parameters                                                                                                                                   
   PR interval (ms)                  181 ± 43                   174 ± 40                       185 ± 45                        −2.325\*            0.025
   QRS duration (ms)                 119 ± 31                   109 ± 28                       125 ± 32                        −5.273\*            \<0.001
   QT interval (ms)                  401 ± 54                   392 ± 48                       406 ± 56                        −2.867\*            0.004
   QTc (ms)                          438 ± 44                   429 ± 37                       443 ± 47                        −3.557\*            \<0.001
   P-wave axis (°)                   46 (30--61)                46 (30--61)                    47 (30--61)                     −0.028^‡^           0.978
   QRS axis (°)                      5 (−33 to 46)              28.5 (−1.5 to 58.0)            −12 (−43 to 36)                 --6.056^‡^          \<0.001
   T-wave axis (°)                   90 (47--150)               59 (19--90)                    116 (90--166)                   −9.792^‡^           \<0.001
   QRS-T angle (°)                   107 ± 54                   45 ± 25                        145 ± 25                        −42.165\*           \<0.001
   Any bundle branch block           194 (38)                   49 (25)                        145 (46)                        21.343^†^           \<0.001
   LBBB                              153 (30)                   32 (17)                        121 (38)                        33.250^†^           \<0.001
   RBBB                              40 (8)                     17 (9)                         23 (7)                          0.387^†^            0.534
  24-h ECG recording                                                                                                                               
   PVC                               495 (38--2449)             154 (14--2242)                 629 (79--2679)                  −2.533^‡^           0.049
   NSVT                              3 (4--37)                  1 (0--19)                      4 (7--61)                       −1.928^‡^           0.041
  Echocardiography                                                                                                                                 
   LVEF (%)                          33 ± 8                     36 ± 8                         31 ± 7                          6.643\*             \<0.001
   LVEDd (cm)                        6.7 ± 0.8                  6.6 ± 0.8                      6.8 ± 0.8                       −3.432\*            0.001
   LVEDs (cm)                        5.7 ± 1.9                  5.7 ± 2.9                      5.7 ± 0.9                       −0.299\*            0.765
   LAD (cm)                          4.90 (4.40--5.40)          4.9 ± 0.8                      5.00 (4.40--5.50)               −1.535^‡^           0.125
   Interventricular septum (cm)      0.9 ± 0.1                  0.9 ± 0.1                      0.9 ± 1.0                       0.341\*             0.733
   Posterior wall (cm)               0.85 (0.80--0.94)          0.90 ± 0.10                    0.85 (0.79--0.95)               −0.456^‡^           0.648
   PAP (mmHg)                        48 ± 12                    45 ± 13                        49 ± 12                         −2.524\*            0.012
  Laboratory examination                                                                                                                           
   Creatinine (mg/L)                 800 (670--1000)            790 (630--930)                 810 (680--1040)                 −1.950^‡^           0.038
   Hemoglobin (10^−4^×mg/L)          132 ± 22                   133 ± 22                       132 ± 22                        0.211\*             0.833
   Sodium (mmol/L)                   142 ± 3                    142 ± 3                        142 ± 4                         0.178\*             0.859
   BNP (10^−6^×mg/L)                 672 (312--1495)            463 (156--1060)                786 (406--1535)                 −4.556^‡^           \<0.001

Data were presented as *n* (%), mean ± SD, or median (IQR). \**t* value; ^†^*χ*^2^ value; ^‡^*Z* value. *P* values were from comparisons between patients with QRS-T angles ≤90°and \>90°. CHF: Congestive heart failure; NYHA: New York Heart Association; ACEI: Angiotensin-converting enzyme inhibitor; ARB: Angiotensin receptor blocker; BNP: B-type natriuretic peptide; ICD: Implantable cardioverter-defibrillator; QTc: Corrected QT; LBBB: Left bundle branch block; RBBB: Right bundle branch block; PVC: Premature ventricular complexes; NSVT: Nonsustained ventricular tachycardia; LVEF: Left ventricular ejection fraction; LVEDd: Left ventricular end-diastolic diameter; LVEDs: Left ventricular end-systolic diameter; LAD: Left atrial diameter; PAP: Pulmonary arterial pressure; SD: Standard deviation; IQR: Interquartile range; 1 mmHg = 0.133 kPa.

All-cause mortality {#sec2-5}
-------------------

During a median follow-up period of 34 months, 121 deaths were recorded. Ninety of 316 patients (28.5%) with a QRS-T angle \>90° reached the primary endpoint compared to 31 of 193 patients (16.1%) with a QRS-T angle ≤90° \[*HR*: 2.4; 95% *CI*: 1.5 -- 3.6, *P* \< 0.001; [Figure 1a](#F1){ref-type="fig"}, and Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}\]. After multivariable Cox regression analysis, the QRS-T angle \>90° remained the most remarkable and significant independent predictor of all-cause mortality \[*HR*: 2.5, 95% *CI*: 1.2--5.1, *P* \< 0.05; Tables [2](#T2){ref-type="table"} and [4](#T4){ref-type="table"}\]. Other variables independently associated with all-cause mortality were NYHA functional class (*HR*: 1.8, 95% *CI*: 1.2 -- 2.6, *P* \< 0.01), age (*HR*: 1.013, 95% *CI*: 1.002--1.024, *P* \< 0.05), QRS interval (*HR*: 1.011, 95% *CI*: 1.003--1.019, *P* \< 0.01), and the use of ACEI/ARB (*HR*: 0.52, 95% *CI*: 0.30--0.92, *P* \< 0.05).

![Kaplan-Meier curves for each endpoint according to frontal QRS-T angle. All-cause mortality (a), cardiac mortality (b), and heart failure rehospitalization (c) were presented, respectively. Survival curves were significantly different between QRS-T angle \>90° and ≤90° for all endpoints.](CMJ-129-1904-g001){#F1}

###### 

Summary of outcome data regarding QRS-T angle

  Items                             QRS-T angle ≤90° (%)   QRS-T angle \>90° (%)   *HR* (95% *CI*)   Adjusted *HR* (95% *CI*)
  --------------------------------- ---------------------- ----------------------- ----------------- --------------------------
  All-cause mortality               31/193 (16.1)          90/316 (28.5)           2.4 (1.5--3.6)    2.5 (1.2--5.1)
  Cardiac mortality                 25/193 (13.0)          79/316 (25.0)           2.4 (1.5--3.9)    1.9 (1.0--3.5)
  Heart failure rehospitalization   41/193 (21.2)          126/316 (39.9)          2.5 (1.7--3.5)    2.3 (1.3--4.2)

Data were presented as *n/N* (%) or 95% *CI*. *HR*: Hazard ratio; *CI*: Confidence interval.

###### 

*HR*s for all-cause mortality in univariate analyses

  Items                      *HR* (95% *CI*)        *β* coefficient   *P*
  -------------------------- ---------------------- ----------------- ---------
  QRS-T angle                2.365 (1.542--3.628)   0.861             \<0.001
  Age                        1.011 (1.003--1.019)   0.029             0.009
  Gender                     1.439 (0.987--2.097)   0.356             0.058
  Current smoker             1.019 (0.684--1.516)   0.367             0.927
  Diabetes mellitus          1.471 (0.985--2.196)   0.406             0.059
  Atrial fibrillation        1.529 (1.063--2.199)   0.544             0.221
  Heart rate                 0.996 (0.987--1.006)   −0.004            0.442
  NYHA                       1.872 (1.432--2.447)   0.605             \<0.001
  Beta-blockers              0.471 (0.325--0.681)   −0.776            \<0.001
  ACEI/ARB                   0.486 (0.317--0.744)   −0.825            0.001
  Loop diuretics             1.417 (0.795--2.525)   0.287             0.237
  Spironolactone             1.239 (0.805--1.908)   0.095             0.330
  Digoxin                    1.075 (0.745--1.550)   0.348             0.701
  Aspirin                    0.858 (0.580--1.269)   −0.043            0.443
  Warfarin                   0.653 (0.304--1.403)   −0.053            0.275
  Amiodarone                 0.517 (0.190--1.404)   −0.337            0.196
  Systolic blood pressure    0.991 (0.981--1.001)   −0.005            0.085
  Diastolic blood pressure   0.986 (0.971--1.001)   −0.006            0.071
  PR interval                1.005 (1.000--1.010)   0.005             0.053
  QRS interval               1.011 (1.006--1.017)   0.011             \<0.001
  QTc                        1.005 (1.000--1.009)   0.005             0.043
  P-wave axis                0.999 (0.993--1.005)   −0.001            0.712
  QRS axis                   1.002 (0.998--1.005)   0.002             0.331
  T-wave axis                1.001 (0.998--1.003)   0.000             0.557
  LBBB                       1.809 (1.244--2.631)   0.615             0.002
  RBBB                       1.546 (1.047--2.926)   0.670             0.053
  PVC                        1.000 (1.000--1.000)   0.000             0.886
  NSVT                       1.001 (0.763--1.374)   −0.011            0.913
  LVEF                       0.967 (0.944--0.991)   −0.044            0.008
  LVEDd                      1.129 (0.892--1.430)   0.162             0.039
  LAD                        1.040 (1.007--1.097)   −0.003            0.626
  BNP                        1.000 (1.000--1.001)   0.000             \<0.001
  Creatinine                 1.006 (0.922--1.016)   −0.002            0.054
  Sodium                     0.904 (0.856--0.954)   0.025             0.066

Variables with a *P*\<0.05 were entered into the multivariable model. *HR*: Hazard ratio; *CI*: Confidence interval; NYHA: New York Heart Association; ACEI: Angiotensin-converting enzyme inhibitor; ARB: Angiotensin receptor blocker; QTc: Corrected QT; LBBB: Left bundle branch block; RBBB: Right bundle branch block; PVC: Premature ventricular complexes; NSVT: Nonsustained ventricular tachycardia; LVEF: Left ventricular ejection fraction; LVEDd: Left ventricular end-diastolic diameter; LAD: Left atrial diameter; BNP: B-type natriuretic peptide.

###### 

*HR*s for all endpoints in multivariable analyses

  Items                             *HR* (95% *CI*)        *β* coefficient   *P*
  --------------------------------- ---------------------- ----------------- -------
  All-cause mortality                                                        
   QRS-T angle                      2.453 (1.188--5.065)   0.951             0.015
   NYHA                             1.780 (1.202--2.634)   0.784             0.004
   Age                              1.013 (1.002--1.024)   0.031             0.016
   QRS interval                     1.011 (1.003--1.019)   0.017             0.008
   ACEI/ARB                         0.523 (0.299--0.915)   −0.607            0.023
  Cardiac mortality                                                          
   QRS-T angle                      1.866 (1.004--3.468)   1.024             0.049
   LBBB                             1.831 (1.126--2.976)   0.687             0.015
   NYHA                             1.668 (1.108--2.510)   0.508             0.014
   Age                              1.032 (1.013--1.052)   0.032             0.001
   BNP                              1.000 (1.000--1.001)   0.000             0.011
  Heart failure Rehospitalization                                            
   QRS-T angle                      2.321 (1.275--4.224)   0.784             0.006
   BNP                              1.051 (1.013--1.079)   0.000             0.008

*P*\<0.05 indicates that this item is an independent predictor of the endpoint. *HR*: Hazard ratio; *CI*: Confidence interval; NYHA: New York Heart Association; ACEI: Angiotensin-converting enzyme inhibitor; ARB: Angiotensin receptor blocker; LBBB: Left bundle branch block; RBBB: Right bundle branch block; BNP: B-type natriuretic peptide.

Cardiac mortality {#sec2-6}
-----------------

Of the 121 deaths, 104 (86.0%) were classified as cardiac deaths. A QRS-T angle \>90° was associated with a significantly higher risk of cardiac death \[25.0% vs. 13.0%; *HR*: 2.4, 95% *CI*: 1.5--3.9, *P* \< 0.001; [Figure 1b](#F1){ref-type="fig"} and [Table 2](#T2){ref-type="table"}\]. This association remained significant after adjustment for other significant covariates in the univariate analysis \[*HR*: 1.9, 95% *CI*: 1.0--3.5, *P* \< 0.05; Tables [2](#T2){ref-type="table"} and [4](#T4){ref-type="table"}\]. LBBB (*HR*: 1.831, 95% *CI*: 1.126--2.976, *P* \< 0.05), NYHA functional class (*HR*: 1.668, 95% *CI*: 1.108--2.510, *P* \< 0.05), age (*HR*: 1.032, 95% *CI*: 1.013--1.052, *P* \< 0.01), and BNP (*HR*: 1.000, 95% *CI*: 1.000--1.001, *P* \< 0.05) were additional independent predictors of cardiac death in the multivariable model after controlling for other covariates \[[Table 4](#T4){ref-type="table"}\].

Heart failure rehospitalization {#sec2-7}
-------------------------------

Rehospitalization due to decompensated heart failure occurred in 126 of 316 patients (39.9%) with a QRS-T angle \>90° and 41 of 193 patients (21.2%) with a QRS-T angle ≤90° \[*HR*: 2.5, 95% *CI*: 1.7--3.5, *P* \< 0.001; [Figure 1c](#F1){ref-type="fig"} and [Table 2](#T2){ref-type="table"}\]. Following adjustment for other variables, the QRS-T angle \>90° (*HR*: 2.321, 95% *CI*: 1.275--4.224, *P* \< 0.01) and BNP (*HR*: 1.051, 95% *CI*: 1.013--1.079, *P* \< 0.01) were independent predictors of heart failure rehospitalization \[[Table 4](#T4){ref-type="table"}\].

Stratified analysis {#sec2-8}
-------------------

We also performed a subgroup analysis stratified by gender. The frontal QRS-T angle was a predictor of all-cause mortality following both univariate and multivariable analyses, exhibiting independent association with all-cause death in both men \[*HR*: 2.29, 95% *CI*: 1.33--3.93, *P* \< 0.01 for men; [Figure 2a](#F2){ref-type="fig"}\] and women \[*HR*: 2.43, 95% *CI*: 1.21--4.90, *P* \< 0.05 for women; [Figure 2b](#F2){ref-type="fig"}\].

![Kaplan-Meier curves for all-cause mortality stratified by gender. Significant difference was observed between QRS-T angle \>90° and ≤90° in both men (a) and women (b) patients.](CMJ-129-1904-g002){#F2}

Other analyses {#sec2-9}
--------------

Following optimized therapy, QRS-T angles at the time of discharge were significantly decreased compared to those at admission (100.9 ± 53.4° vs. 107.2 ± 54.4°, *P* \< 0.001 from Wilcoxon match-pairs analysis), which was more evident in patients with a wide QRS-T angle than that in patients with a narrow angle (−9.9 ± 17.5° vs. −1.1 ± 6.2°, *P* \< 0.01). The correlation between QRS-T angle and well-established risk factors (LVEF, BNP, and NYHA functional class) were also evaluated. Overall, 167 patients rehospitalized in our center were included for analyses. A significant positive correlation was observed between the QRS-T angle and BNP level (*P* = 0.005), and a negative but significant correlation between the QRS-T angle and LVEF was also detected (*P* = 0.048).

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

In a large cohort of 509 patients with IDC, we demonstrated that the frontal QRS-T angle was associated with an increased risk of all-cause mortality and cardiac mortality. The association was independent of well-established predictors, such as age and NYHA functional class. Following multivariable analyses, the adjusted *HR*s for IDC patients with QRS-T angles \>90° were 2.5 and 1.9 for all-cause mortality and cardiac mortality, respectively. For the first time, we also showed that wide QRS-T angles were significantly associated with worsening heart failure in IDC patients and that using optimized therapy during hospitalization, QRS-T angles were significantly narrowed in patients with wide angles.

The frontal QRS-T angle is readily available from routine 12-lead ECGs and reflects both ventricular depolarization and repolarization. Wide QRS-T angles might be associated with myocardial structure abnormalities and electrophysiological alterations and are always documented in patients with ischemia, cardiac hypertrophy, and other nonischemic cardiomyopathies. These structural and functional abnormalities might give patients a higher risk of ventricular arrhythmias and fatal cardiovascular events. Indeed, in our study, the incidence of ventricular ectopic rhythm, including PVC and NSVT on ambulatory monitoring, was higher in IDCM patients with wide QRS-T angles, as were total mortality and cardiac mortality.

The prognostic significance of the frontal QRS-T angle was first reported in the Atherosclerosis Risk in Communities study, which was a population-based multicenter study.\[[@ref15]\] The frontal QRS-T angle was a strong predictor of total mortality, with \>50% increased risk.\[[@ref15]\] Since then, the frontal QRS-T angle has been intensively studied in various populations, including ischemic heart disease (IHD),\[[@ref13]\] acute coronary syndrome,\[[@ref16][@ref17]\] NIDCM,\[[@ref9]\] heart failure,\[[@ref18]\] heart failure with preserved ejection fraction,\[[@ref19]\] and the general population.\[[@ref20][@ref21]\] Most of these studies were performed in mixed cohorts. The heterozygous population of these studies limited the accuracy of the conclusions. To evaluate the predictive value of the frontal QRS-T angle in DCM, the study with the most homogeneous population was a *post hoc* analysis of the DEFINITE trial, which enrolled 458 patients with NIDCM.\[[@ref9]\] Of note, the cohort of the DEFINITE study was not as homogeneous as that of our study because they enrolled all NIDCM patients with a variety of etiologies, such as primary valvular diseases and tachycardia-induced cardiomyopathy, which were all excluded in our study. To the best of our knowledge, the study is a rare prospective study designed to assess the prognostic significance of frontal QRS-T angle in IDC patients.

In our study, despite higher rates of ICD implantation, IDC patients with a QRS-T angle \>90° had a poorer prognosis. Therefore, the significant prognostic value of the frontal QRS-T angle was further highlighted because device therapy is well-documented to improve outcomes in heart failure.\[[@ref22][@ref23]\] After adjustments for all potentially confounding factors, a QRS-T angle \>90° increased the risk of mortality by 145% in IDC patients, which was higher than that in NIDCM patients from the DEFINITE study (by 64%)\[[@ref9]\] and a meta-analysis in a highly mixed population,\[[@ref24]\] whereas this mirrored that in the IHD population (by 140%)\[[@ref13]\] and patients with acute myocardial infarction and reduced LVEF (by 118%).\[[@ref17]\] Our study provides valuable insight into the prognostic implications of frontal QRS-T angle in IDC patients because of its excellent association with the primary and secondary endpoints and it outperforms all other conventional cardiovascular risk factors and well-established predictive factors. It is important and necessary to update the risk stratification method in DCM because of considerable morbidity and mortality.\[[@ref25]\] The current risk stratification method heavily relies on the NYHA functional class and LVEF and is far from optimal. Particularly for the primary prevention of SCD in DCM with device implantation, LVEF is not specific or sensitive enough, missing many SCDs in patients with LVEF \>35%,\[[@ref26][@ref27]\] and only a low rate of ventricular arrhythmias occurs in patients with ICD therapy after a long-term follow-up.\[[@ref28]\] In addition, more than 5% patients receiving ICD develop severe device-related adverse events.\[[@ref29]\] All these problems stress the need for more precise and effective risk stratification criteria. The potential effect of the QRS-T angle in risk stratification has also been supported by other studies: both high- and low-risk patients could be identified. Strauss *et al*.\[[@ref30]\] combined the QRS-T angle with the QRS score and identified high-risk patients with 1-year mortality of 8.8--13.9%. In another study of patients with IHD, patients with QRS-T angle \<100° had no event of ventricular arrhythmia during 2-year follow-up.\[[@ref13]\] It has been commonly accepted that multivariate predictors significantly outperform individual factors in risk stratification;\[[@ref24][@ref26]\] therefore, we expect a comprehensive method combining numerous risk factors including the QRS-T angle to well determine whether a DCM patient is at higher risk.

A wide QRS-T angle is associated with worsening heart failure as first demonstrated in our study. This was evidenced by a higher rate of rehospitalization because of heart failure and because the QRS-T angle showed significant correlation with LVEF, BNP level and NYHA functional class although the mechanism remains unclear. However, the data showed that patients with a QRS-T angle \>90° had significantly larger LVEDd, indicating more significant cardiac remodeling. This cardiac remodeling might have changed the direction of vectors of depolarization and repolarization, resulting in a widened QRS-T angle.\[[@ref19]\] These findings further reinforce the concept that frontal QRS-T angle is a promising predictor for DCM.

Interestingly, in our current study, optimized pharmacotherapy and device implantation led to significantly narrowed frontal QRS-T angle in patients with a wide angle, which is a rare report in DCM. The QRS-T angle change might be a covariate to test whether a patient has good medication compliance in DCM, but other studies are warranted to explore this hypothesis.

Several limitations of our study should be acknowledged. First, this was an observational study conducted in a single center; therefore, the nature of the study design might cause bias. However, the sample size of our study was not small and was rigorously selected as a homogeneous cohort of IDC patients. We applied the multivariable Cox model to adjust for all potential confounders, and the prognostic significance of frontal QRS-T angle after adjustments was consistent with that before adjustment, which supported our conclusions. Second, the use of anticoagulation therapy was far inferior to the prevalence of atrial fibrillation in our cohort, which could also bias our results; however, endpoint verification showed that only four patients died from stroke. Therefore, this bias is unlikely to be large. Third, the use of beta-blockers and ACEI/ARB, both of which are clearly associated with the prognosis of IDC patients, was lower in patients with QRS-T angle \>90° than those \<90°. This might be explained by the observation that patients with wide QRS-T angles had more severe heart failure symptoms and might not be able to tolerate these drugs. We also performed multivariate analysis to adjust for these covariates.

In conclusion, the frontal QRS-T angle is a powerful predictor of all-cause mortality in patients with IDC, independent of well-established prognostic factors such as NYHA functional class, LBBB, age, BNP, and the use of ACEI/ARB. The frontal QRS-T angle also independently predicts the occurrence of cardiac mortality and heart failure rehospitalization. In addition, frontal QRS-T angle changes correlate well with LVEF, BNP, and NYHA class, and optimized therapy significantly narrows this angle, which might be an indicator of medication compliance, but this requires further investigation.
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